In this issue is an overview of the future changes to the UK Cancer Drug Fund as well as approaches ...
Read moreAn update on UK market access at EUCOPE meeting
Read moreEuropean payers have not considered biosimilars to be comparable to their reference products or full...
Read morePharmaceutical companies are able to charge significantly higher prices as these products are addres...
Read moreNew legislation has enabled AIFA to approve reimbursement for Avastin for off-label usage in the tre...
Read moreThis issue includes topics such as the recent AIFA approval of Avastin for off label use in Wet-AMD ...
Read moreUpdates on the latest news on NICE's Value Based Assessment, as well as the approval of ultra-orphan...
Read moreIncluding Sovaldi's $84,000 price, adaptive licence pilots from the EMA and is 2015 a turning point ...
Read moreOur quarterly newsletter shares our perspectives on the latest news, developments and thinking withi...
Read more